Solid-phase luminescent catalyst immunoassay for human serum albumin with hemin as labeling catalyst

1984 ◽  
Vol 156 ◽  
pp. 245-252 ◽  
Author(s):  
Yoshihito Ikariyama ◽  
Shuichi Suzuki ◽  
Masuo Aizawa
1986 ◽  
Vol 32 (4) ◽  
pp. 669-671 ◽  
Author(s):  
J Chesham ◽  
S W Anderton ◽  
C F Kingdon

Abstract In this solid-phase competitive enzymoimmunoassay for albumin in human urine, antiserum to human serum albumin labeled with horseradish peroxidase (EC 1.11.1.7) is incubated with solid-phase-bound human serum albumin in the presence of sample or standard. Results obtained correlate well (r = 0.96) with those of an established fluoroimmunoassay. The present assay covers the range 0.9 to 200 mg/L and can be performed within 1 h. These characteristics, together with the simplicity of the assay protocol, make it very useful for monitoring low concentrations of albumin in urine. Detection of such minimal albuminuria allows initiation of therapy that may prevent development of clinical proteinuria and associated diabetic nephropathy.


1987 ◽  
Vol 65 (8) ◽  
pp. 1927-1934 ◽  
Author(s):  
M. Bouvier ◽  
G. R. Brown ◽  
L. E. St-Pierre

Strategic peptide sequences, patterned on the sequence 136–148 of the primary structure of human serum albumin, have been immobilized on a cross-linked polyacrylamide support using the solid phase peptide synthesis technique. Certain of the resulting materials proved to be efficient adsorbents for bilirubin from aqueous phosphate buffer solution. Amino acids such as lysine and arginine favour the binding of the ligand, whereas glutamic acid reduces it markedly. From Scatchard plots, first and second equilibrium binding constants, in the range of (0.3–9.6) × 104 M−1, were obtained using a site treatment. These binding constants are comparable to that for the binding of bilirubin by a larger fragment of bovine serum albumin that contains the synthesized sequence.


Author(s):  
Wisnu Arfian A. Sudjarwo ◽  
Mathias Thomas Dobler ◽  
Peter A. Lieberzeit

AbstractSolid-phase synthesis is an elegant way to create molecularly imprinted polymer nanoparticles (nano-MIPs) comprising a single binding site, i.e. mimics of antibodies. When using human serum albumin (HSA) as the template, one achieves nano-MIPs with 53 ± 19 nm diameter, while non-imprinted polymer nanoparticles (nano-NIPs) reach 191 ± 96 nm. Fluorescence assays lead to Stern–Volmer plots revealing selective binding to HSA with selectivity factors of 1.2 compared to bovine serum albumin (BSA), 1.9 for lysozyme, and 4.1 for pepsin. Direct quartz crystal microbalance (QCM) assays confirm these results: nano-MIPs bind to HSA immobilized on QCM surfaces. This opens the way for competitive QCM-based assays for HSA: adding HSA to nanoparticle solutions indeed reduces binding to the QCM surfaces in a concentration-dependent manner. They achieve a limit of detection (LoD) of 80 nM and a limit of quantification (LoQ) of 244 nM. Furthermore, the assay shows recovery rates around 100% for HSA even in the presence of competing analytes.


Sign in / Sign up

Export Citation Format

Share Document